Abstract
Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Current Pharmaceutical Design
Title: Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Volume: 16 Issue: 33
Author(s): Pooneh Salari-Sharif and Mohammad Abdollahi
Affiliation:
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Abstract: Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Export Options
About this article
Cite this article as:
Salari-Sharif Pooneh and Abdollahi Mohammad, Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079209
DOI https://dx.doi.org/10.2174/138161210794079209 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Biodiversity and Chemodiversity: Future Perspectives in Bioprospecting
Current Drug Targets Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Design and Development of Preservative Free Herbal Dosage Forms
The Natural Products Journal Dietary Fat Intake and Allergic Diseases
Current Nutrition & Food Science Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Cross-talk of Signaling Pathways in the Pathogenesis of Allergic Asthma and Cataract
Protein & Peptide Letters Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation
Current Topics in Medicinal Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Pathway-Specific, Species, and Sub-Type Counterscreening for Better GPCR Hits in High Throughput Screening
Current Pharmaceutical Biotechnology Importance of Fibroblasts-Myofibroblasts in Asthma-Induced Airway Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Steroids and the Immune Response in Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In vitro Propagation of Cichorium intybus L. and Quantification of Enhanced Secondary Metabolite (Esculin)
Recent Patents on Biotechnology